https://www.selleckchem.com/pr....oducts/cepharanthine
5% vs. 0.0%, p = 0.041). Discharge to home was less common in myosteatotic patients than in non-myosteatotic patients (47.7% vs. 76.9%, p less then 0.001) and also in sarcopenic patients than in non-sarcopenic patients (62.7% vs. 75.5%, p = 0.013). Myosteatotic patients had decreased overall survival according to a Kaplan-Meier analysis (p = 0.002) and in the multivariable-adjusted Cox model (HR = 1.6, p = 0.034). CONCLUSIONS Sarcopenia increases the pneumonia and cardiorespiratory complication rates. Sarcopenia and myosteatosis p
Like
Comment
Share
